Free Trial
NASDAQ:ICU

SeaStar Medical Q2 2024 Earnings Report

SeaStar Medical logo
$3.01 +0.07 (+2.38%)
As of 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

SeaStar Medical EPS Results

Actual EPS
-$10.30
Consensus EPS
-$14.10
Beat/Miss
Beat by +$3.80
One Year Ago EPS
N/A

SeaStar Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SeaStar Medical Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

SeaStar Medical's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

SeaStar Medical Earnings Headlines

Contrasting Aclarion (NASDAQ:ACON) & SeaStar Medical (NASDAQ:ICU)
ICU: YoY revenue increases 69%
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
See More SeaStar Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SeaStar Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SeaStar Medical and other key companies, straight to your email.

About SeaStar Medical

SeaStar Medical (NASDAQ:ICU), Inc. (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR. TriGUARD 3 features an advanced frame and filter design that conforms to varying patient anatomies, enabling physicians to position the device safely and effectively without obstructing critical arterial access routes. SeaStar Medical continues to invest in clinical trials and registry studies to demonstrate the safety and performance of its technology and to support regulatory clearances in North America, Europe and other key markets.

Headquartered in Kansas City, Missouri, SeaStar Medical serves a global customer base through direct sales and distribution partnerships in Europe and parts of Asia Pacific, in addition to its U.S. operations. The company collaborates with interventional cardiologists, cardiac surgeons and research institutions to refine device design and expand indications. Its leadership team brings extensive experience from leading cardiovascular and medical device firms, guiding SeaStar Medical through product development, regulatory interactions and market introduction efforts to address the growing demand for neuroprotection in structural heart care.

View SeaStar Medical Profile